Conversely, sunitinib treatment significantly reduced the magnitude of Tregs (CD4+CD25+FoxP3+) from 10% in control tumor-bearing mice without treatment to 7% (Figure 4A and 4B), and MDSCs (CD11b+Gr-1+) from 1.1% to 0.7% (Figure 4C and 4D). This evidence concerns the gene CD4 and neoplasm.